Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Up 693.5% in March

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 49,200 shares, a growth of 693.5% from the February 28th total of 6,200 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average trading volume of 1,280,500 shares, the short-interest ratio is currently 0.0 days.

Bioxytran Stock Up 3.3 %

OTCMKTS:BIXT traded up $0.00 during trading hours on Wednesday, hitting $0.16. 215,994 shares of the company’s stock traded hands, compared to its average volume of 295,877. The business’s fifty day simple moving average is $0.10 and its two-hundred day simple moving average is $0.10. The firm has a market cap of $13.66 million, a P/E ratio of -15.50 and a beta of 2.00. Bioxytran has a 52 week low of $0.06 and a 52 week high of $0.21.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.